CoreTissue BioEngineering Launches ACL Reconstruction Clinical Trial
CoreTissue BioEngineering, a medtech startup based in Yokohama, has completed the safety evaluation phase of its clinical trial for ACL reconstruction using its medical device ‘Tissue Regenerative Ligament’. The company has now initiated a randomized controlled cohort to further verify the safety and efficacy of the treatment.
YOKOHAMA, Japan–(BUSINESS WIRE)–CoreTissue BioEngineering Inc. (“CTBE”), a medical device start-up (Headquarters: Yokohama City, Kanagawa Prefecture, CEO: Yoji Jokura, Ph.D.) announces that the safety evaluation in the safety cohort of its clinical trial for anterior cruciate ligament (ACL) reconstruction with the medical device “Tissue Regenerative Ligament” (development code: CT-ACL001) sponsored by the company has been completed, and the randomized controlled cohort to verify safety and ef